Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foxy-5 in metastatic breast, colon or prostate cancer
NCT02020291Phase 1Completed
- Sponsor
- WntResearch AB
- Start
- Jun 2013
- Primary completion
- Nov 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Foxy-5 in breast cancer, colorectal cancer (CRC) and prostate cancer (PCa), sponsored by WntResearch AB. Primary endpoint: Safety and tolerability of Foxy-5 at 1 year. Started Jun 2013; status: completed.
02
Drugs
Foxy-5
03
Conditions
breast cancercolorectal cancer (CRC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02020291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02020291.